Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Phase 2
Completed
- Conditions
- Ovarian CancerPeritoneal NeoplasmsFallopian Tube Cancer
- Interventions
- Drug: Chemo Plus Far
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 58
- Registration Number
- NCT00318370
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Hematology and Oncology Specialists, LLC, Metarie, Louisiana, United States
🇺🇸The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath